New Partnerships Added to World Federation of Hemophilia Twinning Program

    Wyeth and Advocacy Community Mark Continued Commitment to Patient Care on
World Hemophilia Day

    COLLEGEVILLE, Pa., April 17 /CNW/ -- In honor of the twentieth
Anniversary of World Hemophilia Day, Wyeth Pharmaceuticals, a division of
Wyeth (NYSE:   WYE), together with the World Federation of Hemophilia (WFH),
announce the addition of five new partnerships to the WFH Twinning Program. 
Begun in 1994, the Twinning Program aims to increase the level of diagnosis
and care for people with hemophilia by pairing emerging treatment centers and
patient organizations with more established centers and organizations around
the world.  Wyeth has been the sole corporate sponsor of the program since
2001, which now includes a total of 31 partnerships worldwide.

    "Wyeth recognizes that effective collaboration between advocacy
organizations and industry can help people with chronic illnesses such as
hemophilia," says Angela Rossetti, Assistant Vice President, and Global
Business Manager for Wyeth Hemophilia.  "Our continued support of the Twinning
Program -- now in its 16th year -- and other advocacy initiatives is part of a
global collaborative effort designed to help patients with hemophilia and
their families receive access to better care."

    The new Twinning partnerships include the following Hemophilia Treatment
Center Twins: Addis Ababa (Ethiopia) and Chapel Hill (North Carolina, USA);
Dakar (Senegal) and Paris (France); Quito (Ecuador) and Caracas (Venezuela);
Manipal (India) and Albuquerque, (New Mexico, USA); Skopje (Macedonia) and
Bonn (Germany).  For more information on the Twinning Program and to view a
video of the Lima (Peru) and Fort Worth (Texas, USA) Twin in action, visit

    "World Hemophilia Day is an opportunity for all of us in the bleeding
disorders community to celebrate our achievements and raise awareness," said
Mark Skinner, WFH president.  "The theme of this year's World Hemophilia Day,
'Together, we care' embodies our spirit of collaboration to work together to
improve care for people with bleeding disorders.  We are grateful to Wyeth for
its support of our programs, especially the Twinning Program, which play a key
role in achieving our vision of Treatment for All."

    Support of Children's Camping Initiatives
    For years, Wyeth has recognized the importance of the summer camp
experience to children in the bleeding disorders community.  Since 1998, Wyeth
has been a major sponsor of Barretstown in Ireland -- an innovative
recreational facility -- where children with serious illnesses, including
children with hemophilia, can participate in a range of fun activities that
also are designed to promote self-confidence, independence, trust and coping
skills.  In addition to its ongoing support, Wyeth works with Barretstown to
help run special camps for children with hemophilia.

    Wyeth is also the founding and exclusive sponsor of NACCHO (North
American Camping Conference of Hemophilia Organizations).  The annual NACCHO
conference is dedicated to the sharing of best practices for bleeding disorder
summer camps.  Through NACCHO, children attending summer camp also have the
opportunity to participate in Leading Edge: Exploring the Outer Limits, a
nationally run adventure program that focuses on self-confidence development
for youth and adolescents in the bleeding disorders community.  Through its
grants to NACCHO, Wyeth has supported 1,000 campers nationally, and 500
campers internationally.

    Wyeth-Sponsored Support Programs
    Education and access to care are critical to the health and well-being of
patients with hemophilia.  In addition to other initiatives that support the
bleeding disorders community, Wyeth proudly awards scholarships to deserving
students who have hemophilia.  For the 2008-2009 academic year alone, Wyeth
awarded up to $100,000 to students with bleeding disorders seeking collegiate,
graduate and vocational degrees.  Wyeth also works to help patients with
hemophilia maintain access to hemophilia therapy.  Through its Factor Resource
Program, Wyeth provides services designed to assist patients experiencing
financial hardship or treatment access issues, including the
Insurance-Coverage Program and the Patient Assistance Program.  Individuals
can get more information about these programs through the Wyeth Hemophilia
Hotline (1-888-999-2349).

    Assisting Advocacy Organizations
    Wyeth also provides assistance to numerous advocacy organizations and
their initiatives, including:
    --  WFH's Global Alliance for Progress (GAP) program, a 10-year healthcare
        development initiative to facilitate earlier and accurate diagnosis
        treatment of people with hemophilia and other bleeding disorders in
        developing countries.
    --  National Hemophilia Foundation's Campaign for Our Future, a program
        designed to provide access to care for all members of the bleeding
        disorders community.
    --  Hemophilia Federation of America's Helping Hands program, which
        provides emergency financial assistance for members of the bleeding
        disorders community.  Last year, Wyeth supported 122 families through
        its grants to the Hemophilia Federation of America.
    --  Coalition for Hemophilia B, an organization that provides information
        about treatment that will improve the quality of life of patients with
        hemophilia B.

    --  International Society for Thrombosis and Haemostasis, which fosters
        advances science relating to the important medical problems of
        thrombosis and abnormalities of haemostasis and vascular biology.

    Wyeth and Hemophilia
    Wyeth works to help improve the health of hemophilia patients through
education, patient assistance programs and by supporting associations
throughout the world. For more information on Wyeth and hemophilia, visit, a comprehensive site that serves as a resource for
patients, parents, and caregivers in the hemophilia community.

    About Wyeth Pharmaceuticals
    Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women's health care, infectious disease, gastrointestinal health,
central nervous system, inflammation, transplantation, hemophilia, oncology,
vaccines and nutritional products.

    Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies.  It is a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines, biotechnology
products, nutritionals and non-prescription medicines that improve the quality
of life for people worldwide.  The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

    The statements in this press release that are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements.  These risks and uncertainties include, among
others, risks related to our proposed merger with Pfizer, including
satisfaction of the conditions of the proposed merger on the proposed
timeframe or at all, contractual restrictions on the conduct of our business
included in the merger agreement, and the potential for loss of key personnel,
disruption in key business activities or any impact on our relationships with
third parties as a result of the announcement of the proposed merger; the
inherent uncertainty of the timing and success of, and expense associated
with, research, development, regulatory approval and commercialization of our
products and pipeline products; government cost-containment initiatives;
restrictions on third-party payments for our products; substantial competition
in our industry, including from branded and generic products; emerging data on
our products and pipeline products; the importance of strong performance from
our principal products and our anticipated new product introductions; the
highly regulated nature of our business; product liability, intellectual
property and other litigation risks and environmental liabilities; the outcome
of government investigations; uncertainty regarding our intellectual property
rights and those of others; difficulties associated with, and regulatory
compliance with respect to, manufacturing of our products; risks associated
with our strategic relationships; global economic conditions; interest and
currency exchange rate fluctuations and volatility in the credit and financial
markets; changes in generally accepted accounting principles; trade buying
patterns; the impact of legislation and regulatory compliance; risks and
uncertainties associated with global operations and sales; and other risks and
uncertainties, including those detailed from time to time in our periodic
reports filed with the Securities and Exchange Commission, including our
current reports on Form 8-K, quarterly reports on Form 10-Q and annual report
on Form 10-K, particularly the discussion under the caption "Item 1A, Risk
Factors" in our Annual Report on Form 10-K for the year ended December 31,
2008, which was filed with the Securities and Exchange Commission on February
27, 2009.  The forward-looking statements in this press release are qualified
by these risk factors.  We assume no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
developments or otherwise.


For further information:

For further information: Media, Danielle Halstrom, Wyeth
Pharmaceuticals, +1-484-865-2020, or Douglas Petkus, Wyeth, +1-973-660-5218,
or Investors, Justin Victoria, Wyeth, +1-973-660-5340 Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890